Cancer, diabetes drugs prop up Japan market as price cut hits 2012 growth
This article was originally published in Scrip
Executive Summary
While there may have been a big increase in the number of new drugs approved in Japan in calendar 2012 (scripintelligence.com, 7 February 2012), growth in the country's pharma market over the same period was held back by the negative impact of the general price revision last April.